Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant

Area of Science:

• Transplant Immunology
• Infectious Diseases
• Pharmacology

Background:

• Cytomegalovirus (CMV) infection and disease pose significant challenges in solid-organ transplantation.
• Current strategies for managing CMV include universal prophylaxis and preemptive monitoring.
• The choice of immunosuppression regimen impacts CMV event rates post-transplant.

Purpose of the Study:

• To evaluate the effectiveness of different immunosuppression strategies in preventing Cytomegalovirus events in kidney transplant recipients.
• To compare the incidence of CMV viremia, infection, and disease between mammalian target of rapamycin (mTOR) inhibitors and calcineurin inhibitors (CNIs).
• To assess the cost-effectiveness and resistance profiles associated with universal CMV prophylaxis versus preemptive strategies.

Main Methods:

• Analysis of registry data and meta-analyses comparing mTOR inhibitors (sirolimus, everolimus) with CNIs plus mycophenolate-based immunosuppression.
• Pooled analysis of three randomized controlled trials (RCTs) in de novo kidney transplant patients comparing cyclosporine with mycophenolate or everolimus.
• A prospective RCT in de novo kidney transplant patients evaluating everolimus-based immunosuppression with low-dose tacrolimus versus standard-dose tacrolimus plus mycophenolate without CMV prophylaxis.

Main Results:

• mTOR inhibitors are associated with significantly fewer CMV events compared to CNI-based regimens in de novo kidney transplant patients.
• Everolimus-based immunosuppression resulted in significantly fewer CMV events (viremia, infection/disease) than mycophenolate.
• Everolimus plus low-dose tacrolimus significantly reduced CMV infection rates compared to standard tacrolimus plus mycophenolate in a prophylaxis-free study.

Conclusions:

• Universal prophylaxis is more cost-effective and reduces CMV resistance compared to preemptive strategies, particularly in high-risk CMV-seropositive donor/CMV-seronegative recipient pairs.
• Everolimus-based immunosuppression demonstrates a significant benefit in reducing CMV events in kidney transplant recipients.
• Further research is needed to understand the long-term benefits of therapeutic strategies aimed at mitigating indirect effects of CMV infections.